Biomarker discovery cohort | Control n = 15 | LBD n = 10 | ||
Gender (M:F) | 5:10 | 6:4 | ||
Mean Age at Sampling (yrs ± SD) | 61 ± 9.9 | 71.9 ± 4.3 | ||
Median disease duration (yrs ± SD) | n/a | 3.4 ± 1.57 | ||
Mean Aβ42 levels (pg/ml ± SD) | 905.41 ± 237 | 695.6 ± 330.7 | ||
Mean h-tau levels (pg/ml ± SD) | 136.58 ± 162 | 523 ± 432 | ||
Mean p-tau181 levels (pg/ml ± SD) | 19.33 ± 11.11 | 52 ± 39 | ||
Validation cohort | Control n = 15 | LBD n = 17 | PD n = 7 | AD n = 16 |
Gender (M:F) | 5:10 | 10:7 | 5:2 | 6:10 |
Mean Age at Sampling (yrs ± SD) | 61 ± 9.9 | 72.1 ± 5.5 | 68.1 ± 3.4 | 78.1 ± 6.67 |
Median disease duration (yrs ± SD) | 3.3 ± 1.9 | 4.1 ± 2.78 | ||
Mean Aβ42 levels (pg/ml ± SD) | 905.41 ± 237 | 663.5 ± 268 | 886.4 ± 232 | 503.68 ± 165.88 |
Mean h-tau levels (pg/ml ± SD) | 136.58 ± 162 | 679 ± 673 | 139 ± 93 | 733.77 ± 481.25 |
Mean p-tau levels (pg/ml ± SD) | 19.33 ± 11.11 | 64.5 ± 48.8 | 26 ± 11 | 93.38 ± 31.55 |